The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.

The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too.

Several new studies find promising evidence that the GLP-1 class of drugs may have a cancer-preventive effect, especially for cancers linked to obesity.

Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.

As more people try weight-loss drugs like Wegovy, some skip the brand name and buy compounded semaglutide from online pharmacies. But some of these may not follow state and federal standards.

This change follows the recent FDA approval of the weight-loss drug for preventing heart attack and stroke in people with overweight or obesity.

People taking weight-loss drugs Ozempic and Wegovy report a dampening of the urge to drink. Here's how the drugs curb cravings and what that could mean for helping treat addiction.